Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Harvard Bioscience (HBIO) Acquisitions (2018)

Harvard Bioscience (HBIO) has disclosed Acquisitions for 6 consecutive years, with $540000.0 as the latest value for Q4 2018.

Quarterly Acquisitions changed N/A to $540000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $540000.0 through Sep 2019, down 99.21% year-over-year, with the annual reading at $68.5 million for FY2018, N/A changed from the prior year.
Acquisitions for Q4 2018 was $540000.0 at Harvard Bioscience, down from $595000.0 in the prior quarter.
The five-year high for Acquisitions was $67.4 million in Q1 2018, with the low at $540000.0 in Q4 2018.
Average Acquisitions over 3 years is $17.1 million, with a median of $4.5 million recorded in 2015.